Synageva BioPharma reports higher Q3 net loss, reiterates guidance for 2012

Synageva BioPharma Corp., a biopharmaceutical company, has reported that net loss for the third quarter ended September 30, 2012 was $10.18 million, or $0.43 loss per share, compared to a net loss of $6.82 million, or $92.21 loss per share, for the same quarter ended September 30, 2011. The company reiterates its previous net operating loss guidance of between $40 and $45 million for 2012.

Total revenues for the third quarter of 2012 were $5.43 million, compared to $184,000 for the same quarter of 2011.

Net loss for the nine months ended September 30, 2012 was $27.76 million, or $1.26 loss per share, compared to a net loss of $17.83 million, or $143.77 loss per share, for the same period ended September 30, 2011.

Total revenues for the nine months ended September 30, 2012 were $10.07 million, compared to $485,000 for the same period ended September 30, 2011.